Swiss National Bank Aerovate Therapeutics, Inc. Transaction History

Swiss National Bank

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	BUY	$12.9 - $18.88 $64,500 - $94,400	5,000 Added 30.86%	21,201 $287,000
Q2 2023 Aug 09, 2023	SELL	$15.63 - $22.01 $37,512 - $52,824	-2,400 Reduced 12.9%	16,201 $277,000
Q1 2023 May 10, 2023	SELL	$19.17 - $27.7 $40,257 - $58,170	-2,100 Reduced 10.14%	18,601 $375,000
Q4 2022 Feb 08, 2023	BUY	$15.92 - $30.52 $329,559 - $631,794	20,701 New	20,701 $606,000

30.7M

186K

269K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $60.1M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.